Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

References for PMC Articles for PubMed (Select 22382151)


Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.

Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, Leidner J, Makhema J, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):131-8. doi: 10.1097/QAI.0b013e3181ffa4f5.


Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H; ASSERT Study Group.

Clin Infect Dis. 2010 Oct 15;51(8):963-72. doi: 10.1086/656417.


Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.

Tassiopoulos K, Read JS, Brogly S, Rich K, Lester B, Spector SA, Yogev R, Seage GR 3rd.

AIDS Behav. 2010 Dec;14(6):1269-78. doi: 10.1007/s10461-010-9705-0.


Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?

Maagaard A, Kvale D.

J Antimicrob Chemother. 2009 Nov;64(5):901-9. doi: 10.1093/jac/dkp316. Epub 2009 Sep 9. Review.


Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?

Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM.

HIV Med. 2009 Aug;10(7):397-406. doi: 10.1111/j.1468-1293.2009.00709.x. Epub 2009 May 12. Review.


No relation between in-utero exposure to HAART and intrauterine growth retardation.

Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C, Blanche S, Warszawski J; ANRS French Perinatal Cohort.

AIDS. 2009 Jun 19;23(10):1235-43. doi: 10.1097/QAD.0b013e32832be0df.


Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).

Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Tréluyer JM; ANRS 12109.

Clin Pharmacol Ther. 2009 Feb;85(2):182-9. doi: 10.1038/clpt.2008.201. Epub 2008 Nov 5.


Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.

Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET.

Ann Pharmacother. 2008 Nov;42(11):1581-5. doi: 10.1345/aph.1L083. Epub 2008 Oct 28.


Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.

Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, Levine M, Bavoux F, Tubiana R, Mandelbrot L, Clavel J, Blanche S; ANRS-Enquête Périnatale Française.

AIDS. 2008 Oct 18;22(16):2165-77. doi: 10.1097/QAD.0b013e328311d18b. Erratum in: AIDS. 2012 May 15;26(8):1047. Carbillon, François F [corrected to Carbillon, L].


Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N.

Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23.


Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG; Pediatric Spectrum of HIV Disease Consortium.

Pediatrics. 2007 Apr;119(4):e900-6. Epub 2007 Mar 12.


Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart.

Fenton TR, Sauve RS.

Eur J Clin Nutr. 2007 Dec;61(12):1380-5. Epub 2007 Feb 14.


Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study.

Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, Frederick M, Handelsman E, Hayani K, Shearer WT; Women and Infants Transmission Study.

J Infect Dis. 2006 Oct 15;194(8):1089-97. Epub 2006 Sep 11.


Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2006 Sep;118(3):e711-8. Epub 2006 Aug 21.


Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.

Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2005 Dec;116(6):e846-54. Epub 2005 Nov 15.


Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.

Poirier MC, Olivero OA, Walker DM, Walker VE.

Toxicol Appl Pharmacol. 2004 Sep 1;199(2):151-61. Review.


Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.

Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, Dearman TG, Von Morgenland W, Allen PC, Valverde C, Castillo AB, Martin RB, Samii VF, Bendele R, Desjardins J, Marthas ML, Pedersen NC, Bischofberger N.

Antimicrob Agents Chemother. 2004 May;48(5):1469-87. Erratum in: Antimicrob Agents Chemother. 2994 Jan;48(6):2346.


Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants.

Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S; Enquête Périnatale Française Study Group.

AIDS. 2003 Sep 26;17(14):2053-61.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk